uu.seUppsala University Publications
Change search
Refine search result
1 - 43 of 43
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Alping, P.
    et al.
    Karolinska Inst, Stockholm, Sweden..
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Fink, K.
    Karolinska Inst, Stockholm, Sweden..
    Gunnarsson, M.
    Orebro Univ Hosp, Orebro, Sweden..
    Lycke, J.
    Univ Gothenburg, Gothenburg, Sweden..
    Nilsson, P.
    Lund Univ, Lund, Sweden..
    Salzer, J.
    Umea Univ, Umea, Sweden..
    Vrethem, M.
    Linkoping Univ, Linkoping, Sweden..
    Langer-Gould, A.
    Kaiser Permanente Southern Calif, Pasadena, CA USA..
    Svenningsson, A.
    Karolinska Inst, Stockholm, Sweden..
    Frisell, T.
    Karolinska Inst, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Stockholm, Sweden..
    Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 714-714Article in journal (Other academic)
  • 2.
    Alping, P.
    et al.
    Danderyd Hosp, Karolinska Inst, Clin Neurosci, Stockholm, Sweden..
    Svenningsson, A.
    Danderyd Hosp, Karolinska Inst, Clin Sci, Stockholm, Sweden..
    Salzer, J.
    Umea Univ, Pharmacol & Clin Neurosci, Umea, Sweden..
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology. Uppsala Univ, Neurosci, Uppsala, Sweden..
    Dahle, C.
    Linkoping Univ, Clin & Expt Med, Linkopin, Sweden..
    Fink, K.
    Danderyd Hosp, Karolinska Inst, Clin Neurosci, Stockholm, Sweden..
    Hillert, J.
    Danderyd Hosp, Karolinska Inst, Clin Neurosci, Stockholm, Sweden..
    Lycke, J.
    Univ Gothenburg, Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, A-M
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Martin, C.
    Danderyd Hosp, Karolinska Inst, Clin Sci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Neurol, Lund, Sweden..
    Walentin, F.
    Orebro Univ Hosp, Neurol, Orebro, Sweden..
    Olsson, T.
    Danderyd Hosp, Karolinska Inst, Clin Neurosci, Stockholm, Sweden..
    Frisell, T.
    Karolinska Inst, Med Solna, Stockholm, Sweden..
    Piehl, F.
    Danderyd Hosp, Karolinska Inst, Clin Neurosci, Stockholm, Sweden..
    Rituximab in multiple sclerosis; data from the swedish MS registry.2016In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 22, no suppl. 3, p. 49-49Article in journal (Refereed)
  • 3. Bjørnevik, Kjetil
    et al.
    Riise, Trond
    Bostrom, Inger
    Casetta, Llaria
    Cortese, Marianna
    Granieri, Enrico
    Holmøy, Trygve
    Kampman, Margitta T
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology. Division of Neurology, Department of Clinical and Experimental Medicine, University of Linköping.
    Magalhaes, Sandra
    Pugliatti, Maura
    Wolfson, Christina
    Myhr, Kjell-Morten
    Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, no 7, p. 1018-1024Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Results from previous studies on a possible interaction between smoking and Epstein-Barr virus (EBV) in the risk of multiple sclerosis (MS) are conflicting.

    OBJECTIVES: To examine the interaction between smoking and infectious mononucleosis (IM) in the risk of MS.

    METHODS: Within the case-control study on Environmental Factors In Multiple Sclerosis (EnvIMS), 1904 MS patients and 3694 population-based frequency-matched healthy controls from Norway, Italy, and Sweden reported on prior exposure to smoking and history of IM. We examined the interaction between the two exposures on the additive and multiplicative scale.

    RESULTS: Smoking and IM were each found to be associated with an increased MS risk in all three countries, and there was a negative multiplicative interaction between the two exposures in each country separately as well as in the pooled analysis (p = 0.001). Among those who reported IM, there was no increased risk associated with smoking (odds ratio (OR): 0.95, 95% confidence interval (CI): 0.66-1.37). The direction of the estimated interactions on the additive scale was consistent with a negative interaction in all three countries (relative excess risk due to interaction (RERI): -0.98, 95% CI: -2.05-0.15, p = 0.09).

    CONCLUSION: Our findings indicate competing antagonism, where the two exposures compete to affect the outcome.

  • 4. Bjørnevik, Kjetil
    et al.
    Riise, Trond
    Casetta, Ilaria
    Drulovic, Jelena
    Granieri, Enrico
    Holmøy, Trygve
    Kampman, Margitta T
    Landtblom, Anne-Marie
    Division of Neurology, Department of Clinical and Experimental Medicine, UHL, County Council, Linköping University, Sweden .
    Lauer, Klaus
    Lossius, Andreas
    Magalhaes, Sandra
    Myhr, Kjell-Morten
    Pekmezovic, Tatjana
    Wesnes, Kristin
    Wolfson, Christina
    Pugliatti, Maura
    Sun exposure and multiple sclerosis risk in Norway and Italy: The EnvIMS study2014In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 20, no 8, p. 1042-1049Article in journal (Refereed)
    Abstract [en]

    OBJECTIVES: The objective of this paper is to estimate the association between multiple sclerosis (MS) and measures of sun exposure in specific age periods in Norway and Italy.

    METHODS: A total of 1660 MS patients and 3050 controls from Italy and Norway who participated in a multinational case-control study (EnvIMS) reported sun habits during childhood and adolescence.

    RESULTS: A significant association between infrequent summer outdoor activity and increased MS risk was found in Norway and in Italy. The association was strongest between the ages of 16 and 18 years in Norway (odds ratio (OR) 1.83, 95% confidence interval (CI) 1.30-2.59), and between birth and age 5 years in Italy (OR 1.56, 95% CI 1.16-2.10). In Italy a significant association was also found during winter (OR 1.42, 95% CI 1.03-1.97). Frequent sunscreen use between birth and the age of 6 years was associated with MS in Norway (OR 1.44, 95% CI 1.08-1.93) after adjusting for outdoor activity during the same period. Red hair (OR 1.67, 95% CI 1.06-2.63) and blonde hair (OR 1.36, 95% CI 1.09-1.70) were associated with MS after adjusting for outdoor activity and sunscreen use.

    CONCLUSION: Converging evidence from different measures underlines the beneficial effect of sun exposure on MS risk.

  • 5.
    Bostrom, I.
    et al.
    Linkoping Univ, Linkoping, Sweden..
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
    Landtblom, A-M
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Adverse events of rituximab in a Swedish MS population sample.2016In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 22, p. 871-871Article in journal (Refereed)
  • 6. Boström, Inger
    et al.
    Stawiarz, Leszek
    Landtblom, Anne-Marie
    epartment of Clinical and Experimental Medicine, Division of Neurology, UHL, Linköping University.
    Age-specific sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg)2014In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 20, no 4, p. 513-514Article in journal (Refereed)
  • 7. Boström, Inger
    et al.
    Stawiarz, Leszek
    Landtblom, Anne-Marie
    Department of Clinical and Experimental Medicine, Division of Neuroscience, Linköping University, Sweden.
    Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg)2013In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 19, no 1, p. 46-52Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Sex ratio in multiple sclerosis has been reported from several geographical areas. The disease is more common in women. In Europe the female-to-male ratio varies from 1.1 to 3.4. A recent study from Canada has reported a significant increase, with time, in female-to-male ratio in multiple sclerosis over the last 100 years.

    OBJECTIVE: The aim of this study was to analyse any change in sex ratio in multiple sclerosis in the Swedish population.

    METHODS: Data from the Swedish MS Register and data from the Swedish National Statistics Office were used to estimate sex ratio by year of birth and year of onset.

    RESULTS: In the analysis of sex ratio by year of birth there were 8834 patients (6271 women and 2563 men) born between 1931 and 1985. The mean women-to-men ratio was 2.62. No clear trend was noted for the women-to-men ratio by year of birth (Spearman's rho = 0.345, p = 0.298, n = 11). The number of patients analysed by year of onset was 9098 during the time period 1946 until 2005. The mean women-to-men ratio was 2.57. No significant change in women-to-men ratio (Spearman's rho = -0.007, p = 0.983, n = 12) with time was observed.

    CONCLUSION: There is no evidence for an increasing women-to-men ratio with time amongst Swedish multiple sclerosis patients.

  • 8.
    Fagius, Jan
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
    Feresiadou, Amalia
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Larsson, Elna-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Radiology.
    Severe relapses and rebound activity after natalizumab discontinuation in MS patients with more than five years of treatment with stable disease course2015In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, p. 297-297Article in journal (Other academic)
  • 9.
    Fagius, Jan
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Lundgren, J.
    Öberg, Gunnar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
    Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation2009In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 15, no 2, p. 229-237Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: During the last 15 years, high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) has globally been performed for severe multiple sclerosis (MS). Most patients have been in progressive phase with long disease duration. As a rule, treatment effect has been minor or moderate. PATIENTS: Since 2004, we have performed HSCT in nine young patients with "malignant" relapsing-remitting MS. Criteria for treatment were short duration of disease; very frequent, severe relapses; recent improvement periods indicating potential for recovery after strong immunosuppression. FINDINGS: Median age at treatment was 27 (range 9-34) years, MS duration 26 (4-100) months, and annualized relapse rate 10 (4-12). Median Disability Status Scale (extended disability status scale, EDSS) at HSCT was 7.0 (3.5-8.0). Median follow-up time April 2008 is 29 (23-47) months. Median EDSS improvement is 3.5 (1.0-7.0), clearly surpassing most previous reports. One patient relapsed mildly with rapid recovery 7 months after HSCT. All patients are otherwise stable, median EDSS being 2.0 (0-6.0). Before HSCT, 61 relapses occurred in 82 patient months; during follow-up, one relapse in 289 patient months. CONCLUSION: This small series of patients with "malignant" relapsing-remitting MS suggests HSCT to be an effective treatment option for this relatively rare disease course. It further suggests that future criteria for HSCT in MS should be close to the present ones.

  • 10.
    Forsberg, L.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Johansson, S.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Frisell, T.
    Karolinska Inst, Dept Med, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Clin Sci, Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Sveningsson, A.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, A-M
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Real world experience of fingolimod after switching multiple sclerosis (MS) therapy; focus on natalizumab naive and experienced persons with MS, respectively2016In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 22, no Suppl. 3, p. 647-648Article in journal (Refereed)
  • 11.
    Forsberg, L.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Johansson, S.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Neurol, Dept Clin Sci, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Sveningsson, A.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, A-M
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Uppsala Univ, Dept Neurosci, Uppsala, Sweden..
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5)2016In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 22, no Suppl. 3, p. 338-339Article in journal (Refereed)
  • 12.
    Forsberg, L.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Johansson, S.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nordin, N.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Svenningsson, A.
    Umea Univ, Pharmacol & Clin Neurosci, Umea, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of dimethyl fumarate2015In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, p. 286-287Article in journal (Other academic)
  • 13.
    Forsberg, L.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Kagstrom, S.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Leandersson, A.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Berglund, A.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.;Biogen, Med Dept, Upplandsvasby, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Sveningsson, A.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5)2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 884-885Article in journal (Other academic)
  • 14.
    Forsberg, L.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Leandersson, A.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Kagstrom, S.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Sveningsson, A.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4)2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 635-636Article in journal (Other academic)
  • 15. Fuevesi, J.
    et al.
    Danielsson, Rolf
    Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Chemistry - BMC, Analytical Chemistry.
    Bencsik, K.
    Hanrieder, Jörg
    Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Chemistry - BMC, Analytical Chemistry.
    Zsiros, V.
    Rajda, C.
    Hakansson, P.
    Uppsala University, Disciplinary Domain of Science and Technology, Physics, Department of Physics and Astronomy.
    Vecsei, L.
    Bergquist, Jonas
    Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Chemistry - BMC, Analytical Chemistry. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Cerebrospinal fluid proteome analysis reveals differentially abundant proteins in multiple sclerosis2014In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 20, p. 180-181Article in journal (Refereed)
  • 16. Greco, Raffaella
    et al.
    Bondanza, Attilio
    Oliveira, Maria Carolina
    Badoglio, Manuela
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Piehl, Fredrik
    Hägglund, Hans
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Haematology.
    Krasulova, Eva
    Simões, Belinda Pinto
    Carlson, Kristina
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Haematology.
    Pohlreich, David
    Labopin, Myriam
    Saccardi, Riccardo
    Comi, Giancarlo
    Mancardi, Gian Luigi
    Bacigalupo, Andrea
    Ciceri, Fabio
    Farge, Dominique
    Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party2015In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, no 2, p. 189-197Article in journal (Refereed)
    Abstract [en]

    BACKGROUND:

    Neuromyelitis optica (NMO) is an inflammatory autoimmune disorder of the central nervous system, hallmarked by pathogenic anti-aquaporin 4 antibodies. NMO prognosis is worse compared with multiple sclerosis.

    OBJECTIVE:

    The European Group for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) conducted a retrospective survey to analyze disease outcome following autologous stem cell transplantation (ASCT).

    METHODS:

    This retrospective multicenter study assessed the efficacy and safety of ASCT in 16 patients suffering from refractory NMO reported to the EBMT registry between 2001 and 2011.

    RESULTS:

    Fifteen patients were successfully mobilized with cyclophosphamide (Cy) and G-CSF, one with G-CSF alone. All patients received an unmanipulated autologous peripheral blood stem cell graft, after conditioning with BEAM plus anti-thymocyte globulin (ATG, n = 9 patients), thiotepa-Cy (n = 3) or Cy (200 mg/kg) plus ATG (n = 4). After a median follow-up of 47 months, three of 16 cases were progression and treatment free, while in the remaining 13 patients further treatments were administered for disability progression or relapse after ASCT. Altogether, relapse-free survival at three and five years was 31% and 10%, respectively, while progression-free survival remained 48% at three and five years.

    CONCLUSIONS:

    In these NMO patients, highly resistant to conventional treatment, ASCT allows for temporary control of the disease, despite a tendency to progress or relapse in the long term.

  • 17.
    Imrell, K.
    et al.
    Karolinska Inst, Stockholm, Sweden..
    Masterman, T.
    Karolinska Inst, Stockholm, Sweden..
    Brynedal, B.
    Karolinska Inst, Stockholm, Sweden..
    Lima, I.
    Karolinska Inst, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Stockholm, Sweden..
    Kockum, I.
    Karolinska Inst, Stockholm, Sweden..
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Genetic load in eleven distantly related individuals from an MS high risk area2015In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, p. 435-436Article in journal (Other academic)
  • 18.
    Johansson, S.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Forsberg, L.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Svenningsson, A.
    Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Danderyd, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, A-M
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology. Uppsala Univ, Dept Neurosci, Uppsala, Sweden..
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Danderyd, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1)2016In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 22, no suppl. 3, p. 336-337Article in journal (Refereed)
  • 19.
    Johansson, S.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Forsberg, L.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Svenningsson, A.
    Umea Univ, Dept Pharmacol & Clin Neurosci, Umea, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and efficacy of natalizumab2015In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, p. 285-286Article in journal (Other academic)
  • 20.
    Johansson, S.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Forsberg, L.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nordin, N.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Svenningsson, A.
    Umea Univ, Dept Pharmacol & Clin Neurosci, Umea, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Clinical Immunology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    The IMSE 2 study: a Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of fingolimod2015In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, p. 284-285Article in journal (Other academic)
  • 21. Jonsson, L.
    et al.
    Holmen, C.
    Hillert, J.
    Nilsson, P.
    Dahle, C.
    Feltelius, N.
    Sveningsson, A.
    Lycke, J.
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Martin, C.
    Piehl, F.
    Olsson, T.
    A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of natalizumab2014In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 20, p. 166-166Article in journal (Refereed)
  • 22. Jonsson, L.
    et al.
    Piehl, F.
    Hillert, J.
    Nilsson, P.
    Dahle, C.
    Feltelius, N.
    Svenningsson, A.
    Lycke, J.
    Fagius, Jan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Wallentin, F.
    Martin, C.
    Olsson, T.
    The immunomodulation and multiple sclerosis epidemiology (IMSE) study; a Swedish nationwide pharmaco-epidemiological and genetic study focussed on long-term safety and efficacy of natalizumab (Tysabri)2013In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 19, no 11, p. 205-205Article in journal (Other academic)
  • 23.
    Kagstrom, S.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Leandersson, A.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Forsberg, L.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Berglund, A.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.;Biogen, Med Dept, Upplandsvasby, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Svenningsson, A.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of natalizumab (IMSE 1)2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 365-366Article in journal (Other academic)
  • 24.
    Kagstrom, S.
    et al.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Leandersson, A.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Forsberg, L.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Berglund, A.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.;Biogen, Med Dept, Upplandsvasby, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Svenningsson, A.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden..
    Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 626-627Article in journal (Other academic)
  • 25. Kobelt, G.
    et al.
    Berg, J.
    Lindgren, P.
    Jonsson, Björn
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health.
    Stawiarz, L.
    Hillert, J.
    Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden2008In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 14, no 5, p. 679-690Article in journal (Refereed)
    Abstract [en]

    Objective To estimate the cost-effectiveness of a new treatment (natalizumab) for multiple sclerosis ( MS) compared with current standard therapy with disease-modifying drugs (DMDs) in Sweden. Methods A Markov model was constructed to illustrate disease progression based on functional disability ( the Expanded Disability Status Scale (EDSS)). The effectiveness of natalizumab was based on a 2-year clinical trial in 942 patients ( AFFIRM). The effectiveness of current DMDs was estimated from a matched sample of 512 patients in the Stockholm MS registry. Patients withdrawing from treatment were assumed to follow the disease course of 824 patients with relapsing-remitting disease at onset in the Ontario natural history cohort. Costs and utilities are based on a recent observational study in 1339 patients. All data sets were available at the patient level. Main results are presented from the societal perspective, over a 20-year time frame, in 2005 Euros ( is an element of 1 = 9.25 SEK). Results In the base case, treatment with natalizumab was less expensive and more effective than treatment with current DMDs. When only healthcare costs were considered, the cost per quality-adjusted life year gained with natalizumab was is an element of 38 145. Results are sensitive only to the time horizon of the analysis and assumptions about effectiveness of natalizumab beyond the trial. Conclusions This cost-effectiveness analysis used registry data, cohort and observational studies to extrapolate the efficacy findings of natalizumab from the AFFIRM clinical trial to measure effectiveness in clinical practice. The analysis results suggest that for the population considered, natalizumab provides an additional health benefit at a similar cost to current DMDs from a societal perspective.

  • 26.
    Kowalec, K.
    et al.
    Univ British Columbia, Vancouver, BC, Canada..
    Wright, G. E. B.
    Univ British Columbia, Vancouver, BC, Canada..
    Drogemoller, B. I.
    Univ British Columbia, Vancouver, BC, Canada..
    Aminkeng, F.
    Univ British Columbia, Vancouver, BC, Canada..
    Bhavsar, A. P.
    Univ British Columbia, Vancouver, BC, Canada..
    Kingwell, E.
    Univ British Columbia, Vancouver, BC, Canada..
    Yoshida, E. M.
    Univ British Columbia, Vancouver, BC, Canada..
    Traboulsee, A.
    Univ British Columbia, Vancouver, BC, Canada..
    Marrie, R. A.
    Univ Manitoba, Winnipeg, MB, Canada..
    Kremenchutzky, M.
    Western Univ, London, ON, Canada..
    Campbell, T.
    Dalhousie Multiple Sclerosis Res Unit, Halifax, NS, Canada..
    Duquette, P.
    Ctr Hosp Univ Montreal, Montreal, PQ, Canada..
    Chalasani, N.
    Indiana Univ, Indianapolis, IN 46204 USA..
    Wadelius, Mia
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical pharmacogenomics and osteoporosis.
    Hallberg, Pär
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical pharmacogenomics and osteoporosis.
    Xia, Z.
    Univ Pittsburgh, Sch Med, Pittsburgh, PA USA..
    De Jager, P.
    Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA..
    Ross, C. J. D.
    Univ British Columbia, Vancouver, BC, Canada..
    Tremlett, H.
    Univ British Columbia, Vancouver, BC, Canada..
    Carleton, B.
    Univ British Columbia, Vancouver, BC, Canada..
    Genome-wide scan identifies association between an interferon regulatory factor-related variant and interferon-beta induced liver injury in multiple sclerosis patients2016In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 22, no 3, p. 834-836Article in journal (Refereed)
  • 27.
    Landtblom, Anne-Marie
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Guala, D.
    Merck GmbH, Stockholm, Sweden..
    Hau, S.
    Malmo Hosp, Malmo, Sweden..
    Jansson, L.
    UAS, Akad Hosp, Neurol Clin, Uppsala, Sweden..
    Martin, C.
    Danderyd Hosp, Neurol, Danderyd, Sweden..
    Fredrikson, S.
    Karolinska Inst, Neurosci, Stockholm, Sweden..
    RebiQoL: A telemedicine patient support program on health related quality of life and adherence in MS patients treated with Rebif2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 425-425Article in journal (Other academic)
  • 28.
    Landtblom, Anne-Marie
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Kristoffersson, A.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience. Univ Linkoping, Gen Hosp, Neurol Policlin, Motala, Sweden..
    Jansson, L.
    UAS, Neurol Clin, Akad Hosp, Uppsala, Sweden..
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Bostrom, I.
    Linkoping Univ, Clin & Expt Med, Linkoping, Sweden..
    Berntsson, S. Ghaderi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience. UAS, Neurol Clin, Akad Hosp, Uppsala, Sweden..
    The diagnosis of OCB-negative MS-patients - an inventory of the Swedish MS register in Uppsala, Sweden2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 439-439Article in journal (Other academic)
  • 29.
    Leandersson, A.
    et al.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Kagstrom, S.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Forsberg, L.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Svenningsson, A.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 888-889Article in journal (Other academic)
  • 30.
    Leandersson, A.
    et al.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Kagstrom, S.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Forsberg, L.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Hillert, J.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Nilsson, P.
    Lund Univ, Dept Neurol, Lund, Sweden..
    Dahle, C.
    Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden..
    Svenningsson, A.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Lycke, J.
    Univ Gothenburg, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden..
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Orebro Univ Hosp, Orebro, Sweden..
    Martin, C.
    Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden..
    Piehl, F.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    Olsson, T.
    Karolinska Inst, Dept Neurosci, Stockholm, Sweden..
    A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2)2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 374-375Article in journal (Other academic)
  • 31. Lossius, Andreas
    et al.
    Riise, Trond
    Pugliatti, Maura
    Bjørnevik, Kjetil
    Casetta, Ilaria
    Drulovic, Jelena
    Granieri, Enrico
    Kampman, Margitta T
    Landtblom, Anne-Marie
    Department of Clinical and Experimental Medicine, Linköping University, Sweden .
    Lauer, Klaus
    Magalhaes, Sandra
    Myhr, Kjell-Morten
    Pekmezovic, Tatjana
    Wesnes, Kristin
    Wolfson, Christina
    Holmøy, Trygve
    Season of infectious mononucleosis and risk of multiple sclerosis at different latitudes;: the EnvIMS Study2014In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 20, no 6, p. 669-674Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Seasonal fluctuations in solar radiation and vitamin D levels could modulate the immune response against Epstein-Barr virus (EBV) infection and influence the subsequent risk of multiple sclerosis (MS).

    METHODS: Altogether 1660 MS patients and 3050 controls from Norway and Italy participating in the multinational case-control study of Environmental Factors In Multiple Sclerosis (EnvIMS) reported season of past infectious mononucleosis (IM).

    RESULTS: IM was generally reported more frequently in Norway (p=0.002), but was associated with MS to a similar degree in Norway (odds ratio (OR) 2.12, 95% confidence interval (CI) 1.64-2.73) and Italy (OR 1.72, 95% CI 1.17-2.52). For all participants, there was a higher reported frequency of IM during spring compared to fall (p<0.0005). Stratified by season of IM, the ORs for MS were 1.58 in spring (95% CI 1.08-2.31), 2.26 in summer (95% CI 1.46-3.51), 2.86 in fall (95% CI 1.69-4.85) and 2.30 in winter (95% CI 1.45-3.66).

    CONCLUSIONS: IM is associated with MS independently of season, and the association is not stronger for IM during spring, when vitamin D levels reach nadir. The distribution of IM may point towards a correlation with solar radiation or other factors with a similar latitudinal and seasonal variation.

  • 32. Lundkvist, M.
    et al.
    Engdahl, E.
    Holmen, C.
    Moverare, Robert
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Respiratory Medicine and Allergology.
    Olsson, T.
    Hillert, J.
    Fogdell-Hahn, A.
    Characterization of anti-natalizumab antibodies in multiple sclerosis patients2013In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 19, no 6, p. 757-764Article in journal (Refereed)
    Abstract [en]

    Background: A small proportion of multiple sclerosis (MS) patients treated with natalizumab develop anti-drug antibodies. Objective: The objective of this paper is to characterize the anti-natalizumab antibody response and to investigate differences between persistently and transiently antibody-positive patients. Methods: Screening for anti-natalizumab antibodies was performed using a standardized bridging ELISA. Antibody-positive samples were further analyzed for IgM and IgG1-4 antibodies using ELISA and ImmunoCAP (R). Results: Anti-natalizumab antibodies developed in 57 of 1379 (4.1%) treated patients after a median treatment duration of three months. Of the positive patients, 20 (35%) patients reverted to negative, 19 (33%) patients were confirmed persistently positive and 18 (32%) patients were unconfirmed positive. Significantly higher anti-natalizumab antibody levels were detected in persistently compared to transiently positive patients. A cutoff value predicting persistence of antibodies could be determined with a sensitivity of 0.84 and a specificity of 0.80. IgM and IgG4 antibody levels were significantly higher in persistently compared to transiently positive patients, and IgG1, IgG2 and IgG4 increased significantly over time. Conclusions: The level of total anti-natalizumab antibodies in a first positive sample can be used to predict patients at risk for persisting antibody positivity. However, neither IgM nor IgG1-4 antibodies could be used to discriminate between transiently and persistently positive patients.

  • 33. Nordin, N.
    et al.
    Hillert, J.
    Piehl, F.
    Svenningsson, A.
    Lycke, J.
    Fagius, Jan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Walentin, F.
    Martin, C.
    Nilsson, P.
    Feltelius, N.
    Dahle, C.
    Olsson, T.
    The immunomodulation and multiple sclerosis epidemiology (IMSE II) study: a Swedish nationwide pharmaco-epidemiological and genetic study focussed on long-term safety and efficacy of fingolimod (Gilenya (R))2013In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 19, no 11, p. 445-446Article in journal (Other academic)
  • 34.
    Novakovic, A.
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
    Krekels, E. H. J.
    Leiden Univ, Leiden Acad Ctr Drug Res, Div Pharmacol, Leiden, Netherlands..
    Savic, R.
    Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA..
    Munafo, A.
    Merck Serono, Merck Inst Pharmacometr, Lausanne, Switzerland..
    Ueckert, Sebastian
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
    Karlsson, Mats O.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
    Covariate analysis using item response theory modelling of expanded disability status scale (EDSS): a case study of cladribine tablets2015In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, p. 704-705Article in journal (Other academic)
  • 35.
    Reinthaler, E. M.
    et al.
    Med Univ Vienna, Inst Neurol, Vienna, Austria..
    Graf, E.
    Helmholtz Zentrum Munchen, Inst Humangenet, Munich, Germany..
    Zrzavy, T.
    Med Univ Vienna, Ctr Brain Res, Vienna, Austria..
    Wieland, T.
    Helmholtz Zentrum Munchen, Inst Humangenet, Munich, Germany..
    Hotzy, C.
    Med Univ Vienna, Inst Neurol, Vienna, Austria..
    Kopecky, C.
    Med Univ Vienna, Dept Internal Med 3, Div Nephrol & Dialysis, Vienna, Austria..
    Schmied, C.
    Med Univ Vienna, Inst Neurol, Vienna, Austria..
    Leutmezer, F.
    Med Univ Vienna, Inst Neurol, Vienna, Austria..
    Keilani, M.
    Med Univ Vienna, Dept Phys Med & Rehabil, Vienna, Austria..
    Lill, C. M.
    Univ Lubeck, Dept Neurol, Focus Program Translat Neurosci, Lubeck, Germany..
    Hoffjan, S.
    Ruhr Univ Bochum, Dept Human Genet, Bochum, Germany..
    Epplen, J. T.
    Ruhr Univ Bochum, Dept Human Genet, Bochum, Germany..
    Zettl, U. K.
    Univ Rostock, Neuroimmunol Sect, Dept Neurol, Rostock, Germany..
    Hecker, M.
    Univ Rostock, Neuroimmunol Sect, Dept Neurol, Rostock, Germany..
    Deutschlaender, A.
    Univ Wurzburg, Dept Neurol, Wurzburg, Germany..
    Ahram, M.
    Univ Jordan, Dept Physiol & Biochem, Amman, Jordan..
    Mustafa, B.
    Univ Jordan, Dept Physiol & Biochem, Amman, Jordan..
    El-Khateeb, M.
    Univ Jordan, NCDEG, Amman, Jordan..
    Vilarino-Guell, C.
    Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada..
    Sadovnick, D. A.
    Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada..
    Zimprich, F.
    Med Univ Vienna, Inst Neurol, Vienna, Austria..
    Tomkinson, B
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden..
    Strom, T. M.
    Helmholtz Zentrum Munchen, Inst Humangenet, Munich, Germany..
    Kristoferitsch, W.
    SMZ Ost Donauspital, Karl Landsteiner Inst Neuroimmunol & Neurodegener, Vienna, Austria..
    Lassmann, H.
    Med Univ Vienna, Ctr Brain Res, Vienna, Austria..
    Zimprich, A.
    Med Univ Vienna, Inst Neurol, Vienna, Austria..
    Mutations in the gene tripeptidyl peptidase II (TPP2) and multiple sclerosis2016In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 22, no suppl. 3, p. 849-849Article in journal (Refereed)
  • 36. Sanna, A
    et al.
    Huang, Yu-Min
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience.
    Arru, G
    Fois, ML
    Link, H
    Rosati, G
    Sotgiu, S
    Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 12008In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 14, no 9, p. 1199-1207Article in journal (Refereed)
    Abstract [en]

    OBJECTIVE: We hypothesized that autoaggressive immune responses observed in multiple sclerosis (MS) could be associated with an imbalance in proportion of immune cell subsets and in cytokine production in response to infection, including viruses. METHODS: We collected blood mononuclear cells (MNC) from 23 patients with MS and 23 sex- and age-matched healthy controls (HC) from the island of Sardinia, Italy, where the prevalence of MS is extraordinarily high. Using flow cytometry, we studied MNC for expression of blood dendritic cell antigens (BDCA)-2 and BDCA-4 surface markers reflecting the proportion of plasmacytoid dendritic cells (pDC) that produce type I interferons (IFNs) after virus challenge and promote Th2/anti-inflammtory cytokine production. In parallel, pro-inflammatory (interleukin [IL]-2, IL-12, IFN-gamma), anti-inflammatory (IL-4, IL-10), and immuno-regulatory/pleiotropic cytokines (type I IFNs including IFN-alpha and beta, IL-6) were measured before and after an in vitro exposure to herpes simplex virus type 1 (HSV-1). RESULTS: The subset of lineage negative (lin(-)), BDCA-2(+) cells was lower in patients with MS compared with HC (0.08 + or - 0.02% vs 0.24 + or - 0.02%; P < 0.001). A similar pattern was observed for lin(-)BDCA-4(+) cells (0.08 + or - 0.02% vs 0.17% + or - 0.03; P < 0.01). Spontaneous productions of IL-6 (45 + or - 10 pg/mL vs 140 + or - 26 pg/mL; P < 0.01) and IL-10 (17 + or - 0.4 pg/mL vs 21 + or - 1 pg/mL; P < 0.05) by MNC were lower in patients with MS compared with HC. Spontaneous production of IL-6 (6.5 + or - 0.15 pg/mL vs 21 + or - 5 pg/mL; P < 0.01 and IL-10 (11 + or - 1 pg/mL vs 14 + or - 3 pg/mL; P < 0.05) by pDC was also lower in patients with MS compared with HC. Exposure of MNC to HSV-1 showed, in both patients with MS and HC, increased production of IFN-alpha, IL-6, and IL-10 but decreased production of IL-4. In response to HSV-1 exposure, productions of IL-6 (165 +or - 28 pg/mL vs 325 + or - 35 pg/mL; P < 0.01) and IL-10 (27 +or - 3 vs 33 + or - 3 P < 0.05) by MNC as well as by pDC (IL-6: 28 + or - 7 vs 39 + or - 12 P < 0.05; IL-10: 14 + or - 1 vs 16 + or - 3 P < 0.05) were lower in patients with MS compared with HC. CONCLUSION: The results implicate a new evidence for altered immune cells and reduced immune responses in response to viral challenge in MS.

  • 37. Tedeholm, H
    et al.
    Lycke, J
    Skoog, B
    Lisovskaja, V
    Hillert, J
    Dahle, C
    Fagius, Jan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Fredrikson, S
    Landtblom, A-M
    Malmeström, C
    Martin, C
    Piehl, F
    Runmarker, B
    Stawiarz, L
    Vrethem, M
    Nerman, O
    Andersen, O
    Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs2013In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 19, no 6, p. 765-774Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: It is currently unknown whether early immunomodulatory treatment in relapsing-remitting MS (RRMS) can delay the transition to secondary progression (SP). OBJECTIVE: To compare the time interval from onset to SP in patients with RRMS between a contemporary cohort, treated with first generation disease modifying drugs (DMDs), and a historical control cohort. METHODS: We included a cohort of contemporary RRMS patients treated with DMDs, obtained from the Swedish National MS Registry (disease onset between 1995-2004, n = 730) and a historical population-based incidence cohort (onset 1950-64, n = 186). We retrospectively analyzed the difference in time to SP, termed the "period effect" within a 12-year survival analysis, using Kaplan-Meier and Cox regression analysis. RESULTS: We found that the "period" affected the entire severity spectrum. After adjusting for onset features, which were weaker in the contemporary material, as well as the therapy initiation time, the DMD-treated patients still exhibited a longer time to SP than the controls (hazard ratios: men, 0.32; women, 0.53). CONCLUSION: Our results showed there was a longer time to SP in the contemporary subjects given DMD. Our analyses suggested that this effect was not solely driven by the inclusion of benign cases, and it was at least partly due to the long-term immunomodulating therapy given.

  • 38.
    Tolf, Andreas
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Granberg, T.
    Karolinska Inst, Dept Radiol, Stockholm, Sweden..
    Larsson, Elna-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Radiology.
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Fagius, Jan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Burman, Joachim
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology.
    Corpus callosum atrophy in MS is halted by autologous haematopoietic stem cell transplantation2017In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 23, p. 1006-1007Article in journal (Other academic)
  • 39. Vassilev, Z.
    et al.
    Li, L.
    Falcone, G.
    Wallander, Mari-Ann
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine.
    Jick, S.
    Bromley, S.
    Mortality and risk factors for death in patients with multiple sclerosis in a large population-based cohort2013In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 19, no 11, p. 343-344Article in journal (Other academic)
  • 40.
    Wesnes, Kristin
    et al.
    Univ Bergen, Dept Clin Med, Bergen, Norway; Haukeland Hosp, Norwegian Multiple Sclerosis Competence Ctr, Dept Neurol, Bergen, Norway.
    Myhr, Kjell-Morten
    Univ Bergen, Dept Clin Med, Bergen, Norway; Haukeland Hosp, Dept Neurol, Norwegian Multiple Sclerosis Registry & Biobank, Bergen, Norway.
    Riise, Trond
    Haukeland Hosp, Norwegian Multiple Sclerosis Competence Ctr, Dept Neurol, Bergen, Norway; Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway.
    Cortese, Marianna
    Univ Bergen, Dept Clin Med, Bergen, Norway; Haukeland Hosp, Norwegian Multiple Sclerosis Competence Ctr, Dept Neurol, Bergen, Norway.
    Pugliatti, Maura
    Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway; Univ Ferrara, Dept Biomed & Specialty Surg Sci, Sect Clin Neurol, Ferrara, Italy.
    Boström, Inger
    Univ Linköping, Div Neurol, Dept Clin & Expt Med, Linköping, Sweden.
    Landtblom, Anne-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Neurology. Univ Linköping, Div Neurol, Dept Clin & Expt Med, Linköping, Sweden.
    Wolfson, Christina
    McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ, Canada.
    Bjørnevik, Kjetil
    Haukeland Hosp, Norwegian Multiple Sclerosis Competence Ctr, Dept Neurol, Bergen, Norway; Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway.
    Physical Activity Is Associated With A Decreased Multiple Sclerosis Risk: The EnvIMS study2018In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 24, no 2, p. 150-157Article in journal (Refereed)
    Abstract [en]

    Background: The lifestyle factors smoking and obesity have been associated with the risk of multiple sclerosis (MS). Physical activity (PA) may also be of importance.

    Objective: To examine the association between PA and MS risk in Italy, Norway, and Sweden and to evaluate the possible influence by established risk factors.

    Methods: In this case–control study, 1904 cases and 3694 controls were asked to report their average weekly amounts of light and vigorous PA during adolescence on a scale ranging from none to more than 3 hours activity. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) and adjusted for potential confounders.

    Results: Vigorous PA was inversely associated with MS risk in the pooled analysis (p-trend < 0.001) with an age- and sex-adjusted OR of 0.74 (95% CI: 0.63–0.87) when comparing the highest and lowest levels. Adjusting for outdoor activity, infectious mononucleosis, body size, and smoking yielded similar results. The association was present in all countries and was not affected by exclusion of patients with early disease onset. Light PA was not associated with the risk of MS.

    Conclusion: Our findings suggest that vigorous PA can modify the risk of developing MS independent of established risk factors.

  • 41. Wesnes, Kristin
    et al.
    Riise, Trond
    Casetta, Ilaria
    Drulovic, Jelena
    Granieri, Enrico
    Holmøy, Trygve
    Kampman, Margitta T
    Landtblom, Anne-Marie
    Division of Neurology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
    Lauer, Klaus
    Lossius, Andreas
    Magalhaes, Sandra
    Pekmezovic, Tatjana
    Bjørnevik, Kjetil
    Wolfson, Christina
    Pugliatti, Maura
    Myhr, Kjell-Morten
    Body size and the risk of multiple sclerosis in Norway and Italy: The EnvIMS study2015In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, no 4, p. 388-395Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: Obesity may be a risk factor for developing multiple sclerosis (MS).

    OBJECTIVE: We examined if body size influences the risk of MS in a population-based, case control study.

    METHODS: A total of 953 cases and 1717 controls from Norway and 707 cases and 1333 controls from Italy reported their body size by choosing a silhouette 1 to 9 (largest) every fifth year from age 5 to 30 and at time of study. The body size-related MS risk was defined by odds ratios (ORs) in logistic regression analyses adjusting for age, smoking and outdoor activity.

    RESULTS: In Norway a large body size (silhouettes 6-9) compared to silhouette 3 increased the risk of MS, especially at age 25 (OR 2.21; 95% CI 1.09-4.46 for men and OR 1.43; 95% CI 0.90-2.27 for women). When comparing silhouette 9 to 1, we found a significant dose-response from age 10 until age 30 peaking at age 25 (sex-adjusted OR 2.83; 95% CI 1.68-4.78). The association was present for at least 15 years prior to disease onset. No significant associations were found in Italy.

    CONCLUSIONS: Obesity from childhood until young adulthood is a likely risk factor for MS with a seemingly stronger effect in Norway than in Italy.

  • 42. Westerlind, Helga
    et al.
    Boström, Inger
    Stawiarz, Leszek
    Landtblom, Anne-Marie
    Linköping University, Sweden/Neurology Unit, General Hospital, Motala, Sweden.
    Almqvist, Catarina
    Hillert, Jan
    New data identify an increasing sex ratio of multiple sclerosis in Sweden2014In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 20, no 12, p. 1578-1583Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: An increasing women-to-men ratio in later birth cohorts of patients with multiple sclerosis (MS) has been observed in several populations and has been hypothesised to be due to one or several environmental factors of importance for disease aetiology. However, in a study based on data from the Swedish MS registry (SMSreg) this ratio was recently reported to be rather stable during the 20(th) century.

    OBJECTIVE: The purpose of this study was to reinvestigate the women-to-men ratio in Sweden based on data from all available data sources, including deceased patients.

    METHOD: We combined data from the SMSreg with data from national patient registers.

    RESULTS: In total we obtained information on 19,510 MS patients born 1931-1985, 13,321 women and 6189 men. The women-to-men ratio increased from 1.70 for patients born in the 1930s to 2.67 for patients born in the 1980s. When comparing the coverage of SMSreg to the full data set, a significantly higher proportion of women born 1931-1935 compared to men born in the same period were found in SMSreg, resulting in a sampling bias hiding the increasing sex ratio in the full material.

    CONCLUSION: The women-to-men ratio in MS has increased in Sweden during the 20(th) century similarly to observations in other western countries.

  • 43.
    Wiberg, M.
    et al.
    Karolinska Inst, Clin Neurosci, S-10401 Stockholm, Sweden.;Swedish Social Insurance Agcy, Anal & Prognosis, Stockholm, Sweden..
    Friberg, E.
    Karolinska Inst, Clin Neurosci, S-10401 Stockholm, Sweden..
    Palmér, E.
    Uppsala University, Disciplinary Domain of Humanities and Social Sciences, Faculty of Social Sciences, Department of Economics. Swedish Social Insurance Agcy, Anal & Prognosis, Stockholm, Sweden..
    Tinghog, P.
    Karolinska Inst, Clin Neurosci, S-10401 Stockholm, Sweden..
    Alexanderson, K.
    Karolinska Inst, Clin Neurosci, S-10401 Stockholm, Sweden..
    Stenbeck, M.
    Karolinska Inst, Clin Neurosci, S-10401 Stockholm, Sweden..
    Earnings among multiple sclerosis patients compared to individuals without MS, in total and for different educational levels and types of occupations - a longitudinal population-based cohort study2015In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 21, p. 23-23Article in journal (Other academic)
1 - 43 of 43
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf